First malaria treatment for babies and infants approved for use
The treatment is dissolvable, including in breast milk, and has a sweet cherry flavour to make it easier to administer.
Eight countries took part in a trial for the new treatment - Burkina Faso, Cote d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania and Uganda - and it is expected to be rolled out across Africa in a matter of weeks.
Until now, there has been no approved malaria treatment for infants weighing less than 4.5kg (around 10lb). Instead, young infants have been treated with versions made for older children.
This brought with it a risk of overdose, because infant livers are not fully developed.
"The available malaria treatments have only been properly tested in children aged at least six months because smaller infants are usually excluded from treatment trials," said Professor Umberto D'Alessandro, from the London School of Hygiene and Tropical Medicine.
Around 30 million babies are born in areas of malaria risk every year, with one survey reporting infections ranging between 3.4% and 18.4% in infants less than six months old.
The drug, known as Coartem Baby or Riamet Baby, will be available on a largely not-for-profit basis, the company behind it, Novartis, has said.
In March, scientists said they were genetically modifying mosquitoes in a bid to stop the spread of the disease.
It would mean a mosquito bite in regions of the world where the disease is endemic no longer carries a potential death sentence.
It comes as scientists warned more than half of the world's population could be at risk of catching diseases transmitted by mosquitoes such as malaria and dengue by the end of the century
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
34 minutes ago
- Washington Post
The first drug to treat infants sick with malaria is approved by Swiss authority
GENEVA — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months.
Forbes
2 hours ago
- Forbes
UNICEF Battles Deadly Cholera Outbreak In Sudan
UNICEF is working with Sudan's Ministry of Health and other partners to protect children from cholera. More supplies and essential medicines are urgently needed. In Khartoum State, Sudan on June 10, 2025, children hold a certificate showing they have received their oral cholera vaccine, delivered by UNICEF. UNICEF has delivered 7.6 million oral cholera vaccines to Sudan this year alone. Cholera can kill in a matter of hours After more than two years of full-scale armed conflict in Sudan, a raging cholera outbreak is putting already vulnerable children at further risk. Since January 2025, a total of 32,070 suspected cholera cases and 742 deaths have been recorded across 15 states. Of the more than 19,000 cases reported in Khartoum State alone, more than 1,700 were among children under the age of 5. The outbreak has spread to 17 out of 18 states. Malnourished young children are particularly vulnerable For children already weakened by conflict, lack of nutritious food and poor sanitation, diseases like cholera and malaria can be deadly without prompt treatment. Caused by eating food or drinking water contaminated with the bacterium Vibro cholerae, cholera can cause acute watery diarrhea with severe dehydration. Untreated, it can claim the life of a small child within hours. The intestinal disease is entirely preventable with regular handwashing with soap and maintaining separate water and sanitation facilities. It's also easily treatable — when the right supplies are available. "It's a pity to have a patient who is severely ill and we can't do anything for him," says Dr. Ahmed Al-Badri. "He's dying in front of us and we know what to do ... but we didn't have anything. We need a lot of supplies." Read the latest UNICEF Sudan situation report Watch the video: UNICEF is working to save children's lives in SudanUNICEF is supporting immunization and improving water quality UNICEF and partners are working with the Federal Ministry of Health to curb the spread of cholera and save lives by delivering oral cholera vaccines, ensuring access to safe water, activating community awareness drives to educate families on proper hygiene practices and distributing critical supplies including oral rehydration salts to support early care. Since the start of 2025, UNICEF has: Related: UNICEF Protects Children in Sudan as Malaria, Cholera Cases Rise Children and adults suffering from cholera receive treatment in the isolation center at Turkish Hospital in Khartoum, Sudan. Between January 2023 and December 2024, the number of cholera cases worldwide more than doubled. More than 1.1 billion people are at risk. UNICEF won't stop helping children in Sudan Sudan remains the world's largest child displacement crisis, with over 5 million children displaced. The ongoing fighting in North Darfur and Kordofan states, combined with continuous displacement and limited access to WASH services and primary health care, are exacerbating the outbreak. Access challenges in conflict-affected areas are further complicating response efforts. Now the rainy season has begun in most cholera-affected states. Heavy rainfall and flooding are known to contribute to the spread of cholera, adding yet another layer of complexity to the current public health emergency. Progress has been made: as of July 2, there has been a general decline in cholera cases in most states in Sudan compared to previous weeks, though cases continue to increase in certain hot spot areas, particularly in states with limited access such as North Darfur, West and South Kordofan states. Despite constraints in funding, UNICEF staff remain on the ground. UNICEF is calling for unimpeded humanitarian access, increased funding and a cessation of hostilities. Learn more about UNICEF's work to support Sudan's children A UNICEF Water, Sanitation and Hygiene and Social Behavioral Change staff member trains a community-based water management committee in Khartoum, to support the provision of chlorine, check the quality of water and ensure access to safe drinking water, following the cholera outbreak. As part of WASH (water, sanitation and hygiene) interventions, UNICEF and partners are implementing community-based interventions aimed at reducing the spread of cholera across affected communities in Khartoum . Every child has the right to a safe and healthy childhood. By supporting UNICEF with flexible funding, you can ensure increased funding and a more equitable allocation of resources and improve outcomes for some of the world's most vulnerable children. Please donate. Right now, the lives of the most vulnerable children hang in the balance as conflicts and crises jeopardize the care and protection that they deserve. Dependable, uninterrupted and effective foreign aid is critical to the well-being of millions of children. Please contact your members of Congress and urge them to support ongoing U.S. investments in foreign assistance. Video edited by Tong Su for UNICEF USA.
8 hours ago
Swiss medicines authority issues first approval for antimalarial drug for treatment of infants
GENEVA -- Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months. The agency said that the decision is significant in part because it's only the third time it has approved a treatment under a fast-track authorization process, in coordination with the World Health Organization, to help developing countries access needed treatment. The newly approved medication, Coartem Baby, is a combination of two antivirals. It is a lower dose version of a tablet previously approved for other age groups, including older children. Dr. Quique Bassat, a malaria expert not affiliated with the Swiss review, said the burden of malaria in very young children is 'relatively low' compared to older kids. But access to such medicines is important to all, he said. 'There is no doubt that any child of whichever age — and particularly very, very young ones or very light-weighted ones — require a treatment,' said Bassat, the director- general of the Barcelona Institute for Global Health, known as ISGlobal. Up to now, antimalarial drugs designed for older children have been administered to small infants in careful ways to avoid overdose or toxicity, in what Bassat called a 'suboptimal solution' that the newly designed medicine could help rectify. 'This is a drug which we know is safe, we know works well, and therefore it will just be available as a new version for a specific age group,' he said. Ruairidh Villar, a Novartis spokesperson, said that eight African countries took part in the assessment and are expected to approve the medicine within 90 days. The company said that it's planning on a rollout on a 'largely not-for-profit basis' in countries where malaria is endemic. Dr. Bhargavi Rao, co-director of the Malaria Centre at the London School of Hygiene and Tropical Medicine, noted that malaria cases continue to rise — especially in crisis-hit countries — despite new vaccines and programs targeting the mosquitoes that spread the parasite. She said access strategies for the new medicine must include a look at where needs are greatest, and urged clarity on pricing. 'We need transparency around what Novartis' 'largely not for profit' statement means including publicly available pricing, which countries will benefit and how long for,' she wrote in an email. Still, she said it was 'significant to finally have a suitable and safe treatment for very young children — more than 20 years since WHO first pre-qualified Coartem for older age groups. She noted the announcement comes as resistance to antimalarials has been growing and many traditional donor countries have been sharply cutting outlays for global health — including for malaria programming and research. The mosquito-borne illness is the deadliest disease in Africa, whose 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to WHO. More than three-quarters of those deaths were among children.
